Global Biopharmaceuticals for Psoriasis Market Growth 2026-2032

June 2026 | 96 pages | ID: G9617CB218AEEN
LP Information

Abstracts

The global Biopharmaceuticals for Psoriasis market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Psoriasis is a common chronic inflammatory skin disease characterized by excessive proliferation of skin cells, resulting in thick, red patches covered with silvery-white scales on the skin surface. The cause of psoriasis is not fully understood, but it is believed to be related to abnormalities in the immune system, especially excessive activity of T cells in the skin. Genetic factors and environmental factors (such as infection, stress, skin damage and certain drugs) may also induce or aggravate the disease.

United States market for Biopharmaceuticals for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Biopharmaceuticals for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Biopharmaceuticals for Psoriasis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Biopharmaceuticals for Psoriasis players cover Amgen, Eli Lilly, Johnson & Johnson, Pfizer, AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the ?Biopharmaceuticals for Psoriasis Industry Forecast? looks at past sales and reviews total world Biopharmaceuticals for Psoriasis sales in 2025, providing a comprehensive analysis by region and market sector of projected Biopharmaceuticals for Psoriasis sales for 2026 through 2032. With Biopharmaceuticals for Psoriasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biopharmaceuticals for Psoriasis industry.

This Insight Report provides a comprehensive analysis of the global Biopharmaceuticals for Psoriasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biopharmaceuticals for Psoriasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Biopharmaceuticals for Psoriasis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biopharmaceuticals for Psoriasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biopharmaceuticals for Psoriasis.

This report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceuticals for Psoriasis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• TNF-?
• Interleukin-17
• Interleukin-23
• Other

Segmentation by Application:

• Hospital
• Clinic
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Amgen
• Eli Lilly
• Johnson & Johnson
• Pfizer
• AbbVie
• Organon
• UCB

Key Questions Addressed in this Report
What is the 10-year outlook for the global Biopharmaceuticals for Psoriasis market?
What factors are driving Biopharmaceuticals for Psoriasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biopharmaceuticals for Psoriasis market opportunities vary by end market size?
How does Biopharmaceuticals for Psoriasis break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Biopharmaceuticals for Psoriasis Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Biopharmaceuticals for Psoriasis by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Biopharmaceuticals for Psoriasis by Country/Region, 2021, 2025 & 2032
2.2 Biopharmaceuticals for Psoriasis Segment by Type
  2.2.1 TNF-?
  2.2.2 Interleukin-17
  2.2.3 Interleukin-23
  2.2.4 Other
  2.2.5 Biopharmaceuticals for Psoriasis Sales by Type
    2.2.5.1 Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
    2.2.5.2 Global Biopharmaceuticals for Psoriasis Revenue and Market Share by Type (2021-2026)
    2.2.5.3 Global Biopharmaceuticals for Psoriasis Sale Price by Type (2021-2026)
2.3 Biopharmaceuticals for Psoriasis Segment by Application
  2.3.1 Hospital
  2.3.2 Clinic
  2.3.3 Other
  2.3.4 Biopharmaceuticals for Psoriasis Sales by Application
    2.3.4.1 Global Biopharmaceuticals for Psoriasis Sale Market Share by Application (2021-2026)
    2.3.4.2 Global Biopharmaceuticals for Psoriasis Revenue and Market Share by Application (2021-2026)
    2.3.4.3 Global Biopharmaceuticals for Psoriasis Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Biopharmaceuticals for Psoriasis Breakdown Data by Company
  3.1.1 Global Biopharmaceuticals for Psoriasis Annual Sales by Company (2021-2026)
  3.1.2 Global Biopharmaceuticals for Psoriasis Sales Market Share by Company (2021-2026)
3.2 Global Biopharmaceuticals for Psoriasis Annual Revenue by Company (2021-2026)
  3.2.1 Global Biopharmaceuticals for Psoriasis Revenue by Company (2021-2026)
  3.2.2 Global Biopharmaceuticals for Psoriasis Revenue Market Share by Company (2021-2026)
3.3 Global Biopharmaceuticals for Psoriasis Sale Price by Company
3.4 Key Manufacturers Biopharmaceuticals for Psoriasis Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Biopharmaceuticals for Psoriasis Product Location Distribution
  3.4.2 Players Biopharmaceuticals for Psoriasis Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BIOPHARMACEUTICALS FOR PSORIASIS BY GEOGRAPHIC REGION

4.1 World Historic Biopharmaceuticals for Psoriasis Market Size by Geographic Region (2021-2026)
  4.1.1 Global Biopharmaceuticals for Psoriasis Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Biopharmaceuticals for Psoriasis Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Biopharmaceuticals for Psoriasis Market Size by Country/Region (2021-2026)
  4.2.1 Global Biopharmaceuticals for Psoriasis Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Biopharmaceuticals for Psoriasis Annual Revenue by Country/Region (2021-2026)
4.3 Americas Biopharmaceuticals for Psoriasis Sales Growth
4.4 APAC Biopharmaceuticals for Psoriasis Sales Growth
4.5 Europe Biopharmaceuticals for Psoriasis Sales Growth
4.6 Middle East & Africa Biopharmaceuticals for Psoriasis Sales Growth

5 AMERICAS

5.1 Americas Biopharmaceuticals for Psoriasis Sales by Country
  5.1.1 Americas Biopharmaceuticals for Psoriasis Sales by Country (2021-2026)
  5.1.2 Americas Biopharmaceuticals for Psoriasis Revenue by Country (2021-2026)
5.2 Americas Biopharmaceuticals for Psoriasis Sales by Type (2021-2026)
5.3 Americas Biopharmaceuticals for Psoriasis Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Biopharmaceuticals for Psoriasis Sales by Region
  6.1.1 APAC Biopharmaceuticals for Psoriasis Sales by Region (2021-2026)
  6.1.2 APAC Biopharmaceuticals for Psoriasis Revenue by Region (2021-2026)
6.2 APAC Biopharmaceuticals for Psoriasis Sales by Type (2021-2026)
6.3 APAC Biopharmaceuticals for Psoriasis Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Biopharmaceuticals for Psoriasis by Country
  7.1.1 Europe Biopharmaceuticals for Psoriasis Sales by Country (2021-2026)
  7.1.2 Europe Biopharmaceuticals for Psoriasis Revenue by Country (2021-2026)
7.2 Europe Biopharmaceuticals for Psoriasis Sales by Type (2021-2026)
7.3 Europe Biopharmaceuticals for Psoriasis Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Biopharmaceuticals for Psoriasis by Country
  8.1.1 Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Biopharmaceuticals for Psoriasis Revenue by Country (2021-2026)
8.2 Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Type (2021-2026)
8.3 Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biopharmaceuticals for Psoriasis
10.3 Manufacturing Process Analysis of Biopharmaceuticals for Psoriasis
10.4 Industry Chain Structure of Biopharmaceuticals for Psoriasis

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Biopharmaceuticals for Psoriasis Distributors
11.3 Biopharmaceuticals for Psoriasis Customer

12 WORLD FORECAST REVIEW FOR BIOPHARMACEUTICALS FOR PSORIASIS BY GEOGRAPHIC REGION

12.1 Global Biopharmaceuticals for Psoriasis Market Size Forecast by Region
  12.1.1 Global Biopharmaceuticals for Psoriasis Forecast by Region (2027-2032)
  12.1.2 Global Biopharmaceuticals for Psoriasis Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Biopharmaceuticals for Psoriasis Forecast by Type (2027-2032)
12.7 Global Biopharmaceuticals for Psoriasis Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Amgen
  13.1.1 Amgen Company Information
  13.1.2 Amgen Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.1.3 Amgen Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Amgen Main Business Overview
  13.1.5 Amgen Latest Developments
13.2 Eli Lilly
  13.2.1 Eli Lilly Company Information
  13.2.2 Eli Lilly Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.2.3 Eli Lilly Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Eli Lilly Main Business Overview
  13.2.5 Eli Lilly Latest Developments
13.3 Johnson & Johnson
  13.3.1 Johnson & Johnson Company Information
  13.3.2 Johnson & Johnson Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.3.3 Johnson & Johnson Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Johnson & Johnson Main Business Overview
  13.3.5 Johnson & Johnson Latest Developments
13.4 Pfizer
  13.4.1 Pfizer Company Information
  13.4.2 Pfizer Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.4.3 Pfizer Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.4.4 Pfizer Main Business Overview
  13.4.5 Pfizer Latest Developments
13.5 AbbVie
  13.5.1 AbbVie Company Information
  13.5.2 AbbVie Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.5.3 AbbVie Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.5.4 AbbVie Main Business Overview
  13.5.5 AbbVie Latest Developments
13.6 Organon
  13.6.1 Organon Company Information
  13.6.2 Organon Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.6.3 Organon Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.6.4 Organon Main Business Overview
  13.6.5 Organon Latest Developments
13.7 UCB
  13.7.1 UCB Company Information
  13.7.2 UCB Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
  13.7.3 UCB Biopharmaceuticals for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  13.7.4 UCB Main Business Overview
  13.7.5 UCB Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Biopharmaceuticals for Psoriasis Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Biopharmaceuticals for Psoriasis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of TNF-?
Table 4. Major Players of Interleukin-17
Table 5. Major Players of Interleukin-23
Table 6. Major Players of Other
Table 7. Global Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 8. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
Table 9. Global Biopharmaceuticals for Psoriasis Revenue by Type (2021-2026) & ($ million)
Table 10. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2021-2026)
Table 11. Global Biopharmaceuticals for Psoriasis Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Biopharmaceuticals for Psoriasis Sale by Application (2021-2026) & (K Units)
Table 13. Global Biopharmaceuticals for Psoriasis Sale Market Share by Application (2021-2026)
Table 14. Global Biopharmaceuticals for Psoriasis Revenue by Application (2021-2026) & ($ million)
Table 15. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application (2021-2026)
Table 16. Global Biopharmaceuticals for Psoriasis Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Biopharmaceuticals for Psoriasis Sales by Company (2021-2026) & (K Units)
Table 18. Global Biopharmaceuticals for Psoriasis Sales Market Share by Company (2021-2026)
Table 19. Global Biopharmaceuticals for Psoriasis Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Company (2021-2026)
Table 21. Global Biopharmaceuticals for Psoriasis Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Biopharmaceuticals for Psoriasis Producing Area Distribution and Sales Area
Table 23. Players Biopharmaceuticals for Psoriasis Products Offered
Table 24. Biopharmaceuticals for Psoriasis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Biopharmaceuticals for Psoriasis Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Biopharmaceuticals for Psoriasis Sales Market Share Geographic Region (2021-2026)
Table 29. Global Biopharmaceuticals for Psoriasis Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Biopharmaceuticals for Psoriasis Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Biopharmaceuticals for Psoriasis Sales Market Share by Country/Region (2021-2026)
Table 33. Global Biopharmaceuticals for Psoriasis Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 36. Americas Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2026)
Table 37. Americas Biopharmaceuticals for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 39. Americas Biopharmaceuticals for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 40. APAC Biopharmaceuticals for Psoriasis Sales by Region (2021-2026) & (K Units)
Table 41. APAC Biopharmaceuticals for Psoriasis Sales Market Share by Region (2021-2026)
Table 42. APAC Biopharmaceuticals for Psoriasis Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 44. APAC Biopharmaceuticals for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 45. Europe Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 46. Europe Biopharmaceuticals for Psoriasis Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 48. Europe Biopharmaceuticals for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Biopharmaceuticals for Psoriasis Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Biopharmaceuticals for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Biopharmaceuticals for Psoriasis
Table 54. Key Market Challenges & Risks of Biopharmaceuticals for Psoriasis
Table 55. Key Industry Trends of Biopharmaceuticals for Psoriasis
Table 56. Biopharmaceuticals for Psoriasis Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Biopharmaceuticals for Psoriasis Distributors List
Table 59. Biopharmaceuticals for Psoriasis Customer List
Table 60. Global Biopharmaceuticals for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Biopharmaceuticals for Psoriasis Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Biopharmaceuticals for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Biopharmaceuticals for Psoriasis Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Biopharmaceuticals for Psoriasis Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Biopharmaceuticals for Psoriasis Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Biopharmaceuticals for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Biopharmaceuticals for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Biopharmaceuticals for Psoriasis Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Biopharmaceuticals for Psoriasis Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Biopharmaceuticals for Psoriasis Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Biopharmaceuticals for Psoriasis Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Biopharmaceuticals for Psoriasis Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Biopharmaceuticals for Psoriasis Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Amgen Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 75. Amgen Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 76. Amgen Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Eli Lilly Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 80. Eli Lilly Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 81. Eli Lilly Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Eli Lilly Main Business
Table 83. Eli Lilly Latest Developments
Table 84. Johnson & Johnson Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 85. Johnson & Johnson Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 86. Johnson & Johnson Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Johnson & Johnson Main Business
Table 88. Johnson & Johnson Latest Developments
Table 89. Pfizer Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 91. Pfizer Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94. AbbVie Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 95. AbbVie Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 96. AbbVie Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. AbbVie Main Business
Table 98. AbbVie Latest Developments
Table 99. Organon Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 100. Organon Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 101. Organon Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Organon Main Business
Table 103. Organon Latest Developments
Table 104. UCB Basic Information, Biopharmaceuticals for Psoriasis Manufacturing Base, Sales Area and Its Competitors
Table 105. UCB Biopharmaceuticals for Psoriasis Product Portfolios and Specifications
Table 106. UCB Biopharmaceuticals for Psoriasis Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. UCB Main Business
Table 108. UCB Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Biopharmaceuticals for Psoriasis
Figure 2. Biopharmaceuticals for Psoriasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biopharmaceuticals for Psoriasis Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Biopharmaceuticals for Psoriasis Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Biopharmaceuticals for Psoriasis Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Biopharmaceuticals for Psoriasis Sales Market Share by Country/Region (2025)
Figure 10. Biopharmaceuticals for Psoriasis Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of TNF-?
Figure 12. Product Picture of Interleukin-17
Figure 13. Product Picture of Interleukin-23
Figure 14. Product Picture of Other
Figure 15. Global Biopharmaceuticals for Psoriasis Sales Market Share by Type in 2026
Figure 16. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Type (2021-2026)
Figure 17. Biopharmaceuticals for Psoriasis Consumed in Hospital
Figure 18. Global Biopharmaceuticals for Psoriasis Market: Hospital (2021-2026) & (K Units)
Figure 19. Biopharmaceuticals for Psoriasis Consumed in Clinic
Figure 20. Global Biopharmaceuticals for Psoriasis Market: Clinic (2021-2026) & (K Units)
Figure 21. Biopharmaceuticals for Psoriasis Consumed in Other
Figure 22. Global Biopharmaceuticals for Psoriasis Market: Other (2021-2026) & (K Units)
Figure 23. Global Biopharmaceuticals for Psoriasis Sale Market Share by Application (2025)
Figure 24. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Application in 2026
Figure 25. Biopharmaceuticals for Psoriasis Sales by Company in 2026 (K Units)
Figure 26. Global Biopharmaceuticals for Psoriasis Sales Market Share by Company in 2026
Figure 27. Biopharmaceuticals for Psoriasis Revenue by Company in 2026 ($ millions)
Figure 28. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Company in 2026
Figure 29. Global Biopharmaceuticals for Psoriasis Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Biopharmaceuticals for Psoriasis Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Biopharmaceuticals for Psoriasis Sales 2021-2026 (K Units)
Figure 32. Americas Biopharmaceuticals for Psoriasis Revenue 2021-2026 ($ millions)
Figure 33. APAC Biopharmaceuticals for Psoriasis Sales 2021-2026 (K Units)
Figure 34. APAC Biopharmaceuticals for Psoriasis Revenue 2021-2026 ($ millions)
Figure 35. Europe Biopharmaceuticals for Psoriasis Sales 2021-2026 (K Units)
Figure 36. Europe Biopharmaceuticals for Psoriasis Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Biopharmaceuticals for Psoriasis Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Biopharmaceuticals for Psoriasis Revenue 2021-2026 ($ millions)
Figure 39. Americas Biopharmaceuticals for Psoriasis Sales Market Share by Country in 2026
Figure 40. Americas Biopharmaceuticals for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 41. Americas Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
Figure 42. Americas Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2026)
Figure 43. United States Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Biopharmaceuticals for Psoriasis Sales Market Share by Region in 2026
Figure 48. APAC Biopharmaceuticals for Psoriasis Revenue Market Share by Region (2021-2026)
Figure 49. APAC Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
Figure 50. APAC Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2026)
Figure 51. China Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 55. India Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Biopharmaceuticals for Psoriasis Sales Market Share by Country in 2026
Figure 59. Europe Biopharmaceuticals for Psoriasis Revenue Market Share by Country (2021-2026)
Figure 60. Europe Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
Figure 61. Europe Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2026)
Figure 62. Germany Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 63. France Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Biopharmaceuticals for Psoriasis Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Biopharmaceuticals for Psoriasis Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Biopharmaceuticals for Psoriasis Sales Market Share by Application (2021-2026)
Figure 70. Egypt Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Biopharmaceuticals for Psoriasis Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Biopharmaceuticals for Psoriasis in 2026
Figure 76. Manufacturing Process Analysis of Biopharmaceuticals for Psoriasis
Figure 77. Industry Chain Structure of Biopharmaceuticals for Psoriasis
Figure 78. Channels of Distribution
Figure 79. Global Biopharmaceuticals for Psoriasis Sales Market Forecast by Region (2027-2032)
Figure 80. Global Biopharmaceuticals for Psoriasis Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Biopharmaceuticals for Psoriasis Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Biopharmaceuticals for Psoriasis Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Biopharmaceuticals for Psoriasis Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Biopharmaceuticals for Psoriasis Revenue Market Share Forecast by Application (2027-2032)